A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Insulin Glargine and Lixisenatide (Soliqua 100/33)

Insulin Glargine and Lixisenatide replaces or supplements natural insulin to control blood sugar in diabetes.

First FDA approval2016-11-21
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
$57.05/unit
1 NDCs benchmarked, lowest of all strengths.
Average NADAC
$57.05
Across all dosage forms in distribution.
Highest NADAC
$57.05
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Insulin Glargine and Lixisenatide used for?

Insulin Glargine and Lixisenatide replaces or supplements natural insulin to control blood sugar in diabetes.

Is there a generic for Insulin Glargine and Lixisenatide?

No. Insulin Glargine and Lixisenatide is brand-only with no generic equivalents currently in market.

How much does my plan pay for Insulin Glargine and Lixisenatide?

Across 329 Part D plans, Insulin Glargine and Lixisenatide averages $57.05/unit (NADAC). Lowest available: $57.05/unit. Highest in distribution: $57.05/unit.

Is Insulin Glargine and Lixisenatide on the FDA shortage list?

No. Insulin Glargine and Lixisenatide is not currently on the FDA Drug Shortage Database.

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Insulin Analog6 alternatives in D1
01
Diluent
Brand: Sterile Diluent
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
02
Insulin Aspart
Brand: .Insulin Aspart Protamine and Insulin Aspart
$6.94Lowest NADAC
0Generic mfrs
$704.9MCY24 Part D spend
Compare →
03
Insulin Aspart Injection
Brand: Fiasp
$6.93Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
04
Insulin Aspart-Szjj
Brand: MERILOG
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
05
Insulin Aspart-Xjhz
Brand: KIRSTY
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
06
Insulin Degludec
Brand: TRESIBA
$9.02Lowest NADAC
0Generic mfrs
$2.69BCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file (1 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.